CEO William Caldwell to Discuss ACTC's Strategies for Development and Commercialization of Novel Stem Cell-Based Medical Treatments
ALAMEDA, Calif.-- (BUSINESS WIRE)--Advanced Cell Technology (ACTC), Inc. (OTCBB:ACTC - News), applying proprietary human embryonic stem (ES) cell technology to the emerging field of regenerative medicine, announced today that William Caldwell IV, Chairman and Chief Executive Officer, has been invited to present an overview of the Company's proprietary stem cell science and therapeutic programs at the upcoming 4th Annual Commercialization of Tissue Engineering and Cell Therapy, to be held December 14 and 15, 2006, in London.
The conference is designed to bring together research, academic and business leaders who are driving progress in cell-based sciences and industry. Attendees and speakers will address fundamental challenges and opportunities of producing cell-based therapies, with a focus on the strategic path to bring products to market.
In his keynote address, Mr. Caldwell will discuss ACTC's unique technologies as well as its overall strategies for developing medically valuable therapies for a number of market segments in medicine and health care. ACTC has pioneered a range of innovations relating to human embryonic stem cells, and is committed to taking a leadership role in the development of stem cell based therapies to cure or treat a range of serious diseases, injuries and degenerative medical conditions.
Mr. Caldwell's presentation is scheduled for December 15, 2006, at 9:10 am GMT. The conference will be held at the Grange Holborn Hotel in London. A downloadable PDF copy of the presentation is available on the ACT website at "http://www.advancedcell.com/conference-presentations/":http://www.advancedcell.com/conference-presentations/
"I believe that we are at a pivotal point in our industry's evolution, where research has begun to show the vast potential of stem cell-based therapies to offer important advances in medical care,” said Mr. Caldwell. "At ACTC, we are already employing innovative solutions in both basic science as well as product applications, and I look forward to sharing our ideas with my colleagues in the extended international community of scientists and business leaders.”
ACTC's mission is to develop stem cell based treatments and therapies for a broad range of disease and injuries. Embryonic stem cells promise to provide a well-characterized and reproducible source of replacement tissue for human clinical studies. One of ACTC's lead development programs applies human embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) for the treatment of retinal degenerative diseases such as macular degeneration and retinitis pigmentosa. Another development program focuses on the use of hESC-derived hemangioblasts for vascular restoration of organs and limbs.
About Advanced Cell Technology, Inc.
Advanced Cell Technology Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
For more information, please visit: "www.advancedcell.com":http://www.advancedcell.com. For investor-specific information and resources, visit "http://www.trilogy-capital.com/tcp/advancedcell":http://www.trilogy-capital.com/tcp/advancedcell. To read or download Advanced Cell's Investor Fact Sheet, please visit "http://www.trilogy-capital.com/tcp/advancedcell/factsheet.html":http://www.trilogy-capital.com/tcp/advancedcell/factsheet.html.
To view recent stock quotes and news, visit "http://www.trilogy-capital.com/tcp/advancedcell/quote.html":http://www.trilogy-capital.com/tcp/advancedcell/quote.html.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
The Investor Relations Group
Investors: "James Carbonara":mailto:firstname.lastname@example.org, 212-825-3210
Media: "Bill Douglass":mailto:email@example.com, 212-825-3210
Trilogy Capital Partners
"Paul Karon":mailto:firstname.lastname@example.org, 800-592-6067
Source: Advanced Cell Technology, Inc.